This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Migraine treated with amitriptyline

Authoring team

Although amitriptyline is not licensed for the prophylactic treatment of migraine.

Amitriptyline 10-150mg daily, at or 1-2 hours before bedtime (1):

  • starting dose 10mg per day
  • titration 10-25 mg
  • maximum dose 150mg per day
  • preventative medications must be titrated slowly to an effective or maximum tolerable dose and continued for at least 6-8 weeks to adequately assess effect
  • consider gradual withdrawal after 6-12 months of effective prophylaxis

Previous BASH guidance noted that amitriptyline may be a useful prophylaxis if migraine coexists with (2):

  • troublesome tension-type headache
  • another chronic pain condition
  • disturbed sleep
  • depression - note that except in the case of depression, it is wise to explain the choice of this drug to patients who do not consider themselves depressed or they may reject it

Amitryptiline may prevent migraine by blocking 5-HT2 receptors on cerebral vessels and central neurones.

The usual initial dose is 10mg and this dose is increased in a step-wise manner (usually every two to four weeks) by 10mg per day.

Check the respective summary of product characteristics before prescribing this drug.

Reference:

  1. British Association for the Study of Headache (BASH) guidelines, 2019.
  2. British Association for the Study of Headache (BASH) guidelines, 2004.

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.